勘误：黎巴嫩某医疗中心耐碳青霉烯类和头孢他啶-阿维巴坦的肠杆菌科细菌的分子特征及基因的水平传播
Corrigendum: Molecular characterization of carbapenem and ceftazidime-avibactam-resistant Enterobacterales and horizontal spread of gene at a Lebanese medical center.
作者信息
Sobh Ghena, Araj George F, Finianos Marc, Sourenian Tsolaire, Hrabak Jaroslav, Papagiannitsis Costas C, Chaar Mira El, Bitar Ibrahim
机构信息
Department of Pathology and Laboratory Medicine, American University of Beirut Medical Center, Beirut, Lebanon.
Department of Microbiology, Faculty of Medicine, University Hospital in Pilsen, Charles University, Pilsen, Czechia.
出版信息
Front Cell Infect Microbiol. 2024 Jul 31;14:1466718. doi: 10.3389/fcimb.2024.1466718. eCollection 2024.
Abstract
[This corrects the article DOI: 10.3389/fcimb.2024.1407246.].
摘要
[本文更正了文章DOI：10.3389/fcimb.2024.1407246。]
相似文献
1
Corrigendum: Molecular characterization of carbapenem and ceftazidime-avibactam-resistant Enterobacterales and horizontal spread of gene at a Lebanese medical center.勘误：黎巴嫩某医疗中心耐碳青霉烯类和头孢他啶-阿维巴坦的肠杆菌科细菌的分子特征及基因的水平传播
Front Cell Infect Microbiol. 2024 Jul 31;14:1466718. doi: 10.3389/fcimb.2024.1466718. eCollection 2024.
2
Molecular characterization of carbapenem and ceftazidime-avibactam-resistant Enterobacterales and horizontal spread of gene at a Lebanese medical center.黎巴嫩某医学中心耐碳青霉烯类和头孢他啶-阿维巴坦类肠杆菌科细菌的分子特征及 基因的水平传播
Front Cell Infect Microbiol. 2024 Jun 19;14:1407246. doi: 10.3389/fcimb.2024.1407246. eCollection 2024.
3
Efficacy of ceftazidime/avibactam and plazomicin on carbapenem-resistant Klebsiella pneumoniae and Escherichia coli.头孢他啶/阿维巴坦和硫酸帕拉米韦对碳青霉烯类耐药肺炎克雷伯菌和大肠埃希菌的疗效。
Acta Microbiol Immunol Hung. 2024 Jun 5;71(2):110-120. doi: 10.1556/030.2024.02292. Print 2024 Jul 2.
4
Activity of Cefepime-Zidebactam, Ceftazidime-Avibactam, and Other Comparators against Clinical Isolates of , Pseudomonas aeruginosa, and Acinetobacter baumannii: Results from China Antimicrobial Surveillance Network (CHINET) in 2018.头孢吡肟-齐他培南、头孢他啶-阿维巴坦及其他对照药物对临床分离的铜绿假单胞菌、鲍曼不动杆菌的活性：2018 年中国抗菌药物监测网（CHINET）的结果。
Antimicrob Agents Chemother. 2020 Dec 16;65(1). doi: 10.1128/AAC.01726-20.
5
Dynamic evolution of ceftazidime-avibactam resistance from a single patient through the IncX3_NDM-5 plasmid transfer and bla mutation.从单个患者体内通过 IncX3_NDM-5 质粒转移和 bla 突变导致头孢他啶-阿维巴坦耐药性的动态演变。
Int J Antimicrob Agents. 2024 Aug;64(2):107228. doi: 10.1016/j.ijantimicag.2024.107228. Epub 2024 May 31.
6
Acquisition of a Stable and Transferable -Positive Plasmid With Low Fitness Cost Leading to Ceftazidime/Avibactam Resistance in KPC-2-Producing During Treatment.在治疗过程中，携带低适应性成本的稳定且可转移的头孢他啶/阿维巴坦耐药阳性质粒导致 KPC-2 产酶株获得耐药性。
Front Cell Infect Microbiol. 2021 Jul 20;11:658070. doi: 10.3389/fcimb.2021.658070. eCollection 2021.
7
[In Vitro Activity of Ceftazidime-avibactam and Colistin Against Carbapenem-Resistant Klebsiella pneumoniae Clinical Isolates].头孢他啶-阿维巴坦与黏菌素对耐碳青霉烯类肺炎克雷伯菌临床分离株的体外活性
Mikrobiyol Bul. 2022 Apr;56(2):218-229. doi: 10.5578/mb.20229803.
8
Clinical carbapenem-resistant isolates simultaneously harboring , types and qnrS genes from the Kingdom of Bahrain: Resistance profile and genetic environment.来自巴林王国的同时携带 、 和 qnrS 基因的临床耐碳青霉烯 分离株：耐药谱和遗传环境。
Front Cell Infect Microbiol. 2022 Oct 11;12:1033305. doi: 10.3389/fcimb.2022.1033305. eCollection 2022.
9
High proportion of carbapenemase-producing Escherichia coli and Klebsiella pneumoniae among extended-spectrum β-lactamase-producers in Nigerian hospitals.在尼日利亚医院中，产生超广谱β-内酰胺酶的大肠埃希菌和肺炎克雷伯菌中高产碳青霉烯酶的比例很高。
J Glob Antimicrob Resist. 2020 Jun;21:8-12. doi: 10.1016/j.jgar.2019.09.007. Epub 2019 Sep 13.
10
In vitro activity of Ceftazidime-Avibactam and its comparators against Carbapenem resistant Enterobacterales collected across India: results from ATLAS surveillance 2018 to 2019.体外研究头孢他啶-阿维巴坦及其对照药物对 2018 至 2019 年在印度收集的耐碳青霉烯类肠杆菌科的活性：ATLAS 监测结果。
Diagn Microbiol Infect Dis. 2022 May;103(1):115652. doi: 10.1016/j.diagmicrobio.2022.115652. Epub 2022 Jan 31.
Zotero 插件